Cargando…
Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease
INTRODUCTION: Bronchodilators are the cornerstone of chronic obstructive pulmonary disease (COPD) therapy and long-acting muscarinic antagonists (LAMAs) as a mono or combination treatment play a pivotal role. Several LAMAs are already available on the market in different formulations, but developing...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733406/ https://www.ncbi.nlm.nih.gov/pubmed/33324119 http://dx.doi.org/10.2147/JEP.S259330 |
_version_ | 1783622263726145536 |
---|---|
author | Ora, Josuel Coppola, Angelo Cazzola, Mario Calzetta, Luigino Rogliani, Paola |
author_facet | Ora, Josuel Coppola, Angelo Cazzola, Mario Calzetta, Luigino Rogliani, Paola |
author_sort | Ora, Josuel |
collection | PubMed |
description | INTRODUCTION: Bronchodilators are the cornerstone of chronic obstructive pulmonary disease (COPD) therapy and long-acting muscarinic antagonists (LAMAs) as a mono or combination treatment play a pivotal role. Several LAMAs are already available on the market in different formulations, but developing a new compound with a higher M3 receptor selectivity and a lower affinity to M2 receptors to increase the therapeutic effect and minimize the adverse effects is still a goal. Moreover, new formulations could improve adherence to therapy. AREAS COVERED: This systematic review assesses investigational long-acting muscarinic antagonist in Phase I and II clinical trials over the last decade. It offers insights on whether LAMAs and/or their new formulations in clinical development can become effective treatments for COPD in the future. EXPERT OPINION: Research on LAMA seems to have come to a standstill, the few new molecules under study do not show distinctive characteristics compared to the previous ones. Muscarinic antagonist/β2-agonist (MABAs) appear to be the major innovation currently under investigation, and they could theoretically open new research frontiers on the effect between adrenergic and muscarinic interaction in the same cell. |
format | Online Article Text |
id | pubmed-7733406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-77334062020-12-14 Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease Ora, Josuel Coppola, Angelo Cazzola, Mario Calzetta, Luigino Rogliani, Paola J Exp Pharmacol Review INTRODUCTION: Bronchodilators are the cornerstone of chronic obstructive pulmonary disease (COPD) therapy and long-acting muscarinic antagonists (LAMAs) as a mono or combination treatment play a pivotal role. Several LAMAs are already available on the market in different formulations, but developing a new compound with a higher M3 receptor selectivity and a lower affinity to M2 receptors to increase the therapeutic effect and minimize the adverse effects is still a goal. Moreover, new formulations could improve adherence to therapy. AREAS COVERED: This systematic review assesses investigational long-acting muscarinic antagonist in Phase I and II clinical trials over the last decade. It offers insights on whether LAMAs and/or their new formulations in clinical development can become effective treatments for COPD in the future. EXPERT OPINION: Research on LAMA seems to have come to a standstill, the few new molecules under study do not show distinctive characteristics compared to the previous ones. Muscarinic antagonist/β2-agonist (MABAs) appear to be the major innovation currently under investigation, and they could theoretically open new research frontiers on the effect between adrenergic and muscarinic interaction in the same cell. Dove 2020-12-08 /pmc/articles/PMC7733406/ /pubmed/33324119 http://dx.doi.org/10.2147/JEP.S259330 Text en © 2020 Ora et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Ora, Josuel Coppola, Angelo Cazzola, Mario Calzetta, Luigino Rogliani, Paola Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease |
title | Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease |
title_full | Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease |
title_fullStr | Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease |
title_full_unstemmed | Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease |
title_short | Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease |
title_sort | long-acting muscarinic antagonists under investigational to treat chronic obstructive pulmonary disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733406/ https://www.ncbi.nlm.nih.gov/pubmed/33324119 http://dx.doi.org/10.2147/JEP.S259330 |
work_keys_str_mv | AT orajosuel longactingmuscarinicantagonistsunderinvestigationaltotreatchronicobstructivepulmonarydisease AT coppolaangelo longactingmuscarinicantagonistsunderinvestigationaltotreatchronicobstructivepulmonarydisease AT cazzolamario longactingmuscarinicantagonistsunderinvestigationaltotreatchronicobstructivepulmonarydisease AT calzettaluigino longactingmuscarinicantagonistsunderinvestigationaltotreatchronicobstructivepulmonarydisease AT roglianipaola longactingmuscarinicantagonistsunderinvestigationaltotreatchronicobstructivepulmonarydisease |